Sanofi's 'Miracle Spaceship' Docks at CIIE, Launching a New Chapter in Healthy China Initiative

Forty Years of Abundant Achievements in China

ShanghaiNovember 6, 2022PR Newswire -- Sanofi, a global leading innovative pharmaceuticals and healthcare company, attended the fifth China International Import Expo today. As a "full attendee" participating for five consecutive years, Sanofi, which has been in China for forty years, showcased its corporate mission."Explore Scientific Wonders, Revitalize Life's Radiance"Themed "Miracle Spaceship" loaded with multiple innovative achievements, conveying the spirit of innovation and China's commitment to the world. At this year's event, Sanofi presents strategic innovations from its full range of product fields including immunology, inflammation, rare diseases, vaccines, chronic diseases, and consumer healthcare. Five key products will make their debut in China, marking the beginning of a new journey to support Healthy China for the next forty years.

"As one of the hallmarks of China's high-level opening-up, the CIIE brings tremendous opportunities to numerous multinational companies, including Sanofi. This year marks our fifth consecutive participation in the CIIE. We look forward to showcasing our innovative achievements and renewed mission through this significant platform, conveying our spirit of innovation and commitment to China to the world."Wang Shi, President of Sanofi Greater ChinaSaid, ""We are highly focused on the long-term stable development in the Chinese market. Moving forward, we will continue to adhere to a patient-centered approach, increase investment in research and development and innovation, collaborate with partners from all sectors, and relentlessly pursue scientific breakthroughs, supporting the sustainable development of China's local healthcare ecosystem."

Sanofi China Leadership Team Officially Launches Sanofi's Fifth CIIE

Three Major Exhibition Areas Shine, Five New Products Debut Together

Sanofi has established a new mission for the company this year — "Pursuing scientific miracles, revitalizing the brilliance of life." The exhibition booth this year is designed around this theme, with the concept of a "Miracle Spaceship," and includes sections such as"Four Decades of Partnership in China," "Revitalizing the Radiance of Life," and "Innovation-Driven Healthy China"Three major themed exhibition areas, as well as the "Miracle" cloud booth, showcase the essence of important milestones from the past forty years both online and offline. This includes efforts to create a better life for patients and employees in China, achievements in building a digital ecosystem, and the blueprint for future star innovative products.

Five-time Participant in CIIE, Sanofi Highlights Innovative Exhibits5Debut Innovative Products, including: three products in the fields of immune inflammation and rare diseases — Dupixent, which expands the new indication for moderate to severe atopic dermatitis to the infant population.^®(The only systemic treatment for atopic dermatitis covering the entire population), China debut of Nexviazyme^®*(A New Generation of Enzyme Replacement Therapy for Pompe Disease) and Cablivi^®* (The world’s first approved nanobody drug, as well as the first targeted treatment for acquired thrombotic thrombocytopenic purpura (aTTP)); one preventive product making its global debut — Beyfortus (nirsevimab) * (the world’s first and only long-acting monoclonal antibody for RSV prevention that can be widely used in infants); and one chronic disease product — the innovative combination diabetes treatment Soliqua, developed for Chinese patients. ^TM (iGlarLixi*)。

During the exhibition, a special AD-themed exhibition named "Life Trapped by Itch" was presented. Based on the real-life experiences of patients, it vividly portrayed the dual physical and psychological challenges faced by individuals with atopic dermatitis, aiming to raise societal awareness about this patient group and deepen understanding of this highly prevalent disease.

AD Concept Exhibition: A Life Trapped by Itch

In terms of vaccine innovation, Sanofi Vaccines, in collaboration with Shenzhen Zhiliaoyun Technology Co., Ltd. and the Chinese Academy of Sciences, has launched a new generation of intelligent unmanned vaccine inoculation cabins. Sitting inside this new inoculation cabin, the recipient only needs to roll up their sleeve, expose the inoculation site, and the machine will quickly complete the injection after disinfection. On average, the entire process takes only 35 seconds. Additionally, the cabin is equipped with full-standard cold chain storage for all environmental conditions and automatic vaccine recognition functions, enabling vaccine traceability and secure storage, ensuring "zero-error" vaccine retrieval in the vaccination scenario.

Sanofi will also premiere a science popularization micro-film on cardiovascular diseases, and announce the launch of a video account called "Li Care", which focuses on the popularization of cardiovascular disease knowledge. Sanofi will collaborate with social media bloggers and the medical community to create innovative science popularization content and methods, setting new trends in health education.

As a "pioneer" in the digitalization of the healthcare field, Sanofi has introduced a new phase of digital progress. At this exhibition booth, the company showcased a digital ecosystem matrix comprising eight innovative projects. Starting from rare diseases, cardiovascular diseases, and atopic dermatitis, it covers the entire patient journey with a digital chain that spans from early screening, diagnosis, and treatment to daily disease management.

Benefiting from the "Spillover Effects" of CIIE, Accelerating Innovation with Chinese Partners

The "spillover effect" brought by the CIIE has greatly benefited Sanofi. For instance, after its "debut" at the first CIIE, Dupixent expanded its new indications for moderate to severe atopic dermatitis to include infants and young children.^®This has activated the "China Speed": it was approved in 2020, two years ahead of schedule; it took only 25 days from approval to drug supply; within five months of its market launch, it was included in China's national medical insurance; in 2021, Dupixent^®Approved for adolescent indications; this year, Dupixent^®Recently approved for use in children aged 6 and above and adults, becoming the only targeted biologic agent currently approved in China for the treatment of moderate to severe atopic dermatitis in children, adolescents, and adults.

Because of this, Sanofi remains firmly committed to its long-term promise to China, fully leveraging the advantages of its global R&D capabilities and local insights, and will participate more actively in China's innovation ecosystem. At this year’s CIIE, Sanofi will announce strategic cooperation agreements with partners such as Shenzhen CDC, Health Cloud, and CR Sanjiu, joining hands to build a localized innovation ecosystem. Among these, Sanofi and its "old friend" JD Health will announce an upgrade in their collaboration in the field of internet healthcare. The two parties will expand their existing cooperation from the chronic disease sector to the atopic dermatitis (AD) treatment area. By creating the first one-stop AD online full-process management platform, they aim to meet the more diverse healthcare needs of atopic dermatitis patients in the digital age.

The forty-year story of China is a brilliant chapter in which Sanofi has developed alongside the era of healthcare. The "Miracle Spaceship" is ready to embark on a new 40-year journey, continuing to paint a new picture of China with "people's health as the top priority." With innovative insights into industry development and a fervent passion for exploring scientific miracles for patients, Sanofi remains committed to its promise in China. It aims to lead the transformation and development of China’s healthcare industry together with like-minded partners, jointly revolutionizing medical practices, and contributing positively to building a Healthy China.

* The Product/Indications have not been approved for marketing in China, limited to2022Displayed at the China International Import Expo

Sanofi's Fifth CIIE Booth Diagram